Clinical Trials Logo

Liver Neoplasm clinical trials

View clinical trials related to Liver Neoplasm.

Filter by:

NCT ID: NCT05848947 Completed - Clinical trials for Carcinoma, Hepatocellular

SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA

MAApping
Start date: April 25, 2023
Phase: Phase 4
Study type: Interventional

The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatocellular carcinoma.

NCT ID: NCT05723705 Not yet recruiting - Liver Cancer Clinical Trials

Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)

LIVEROBOT
Start date: April 2023
Phase:
Study type: Observational

LIVEROBOT is a collaboration of high-volume liver surgical centers in Europe (≥60 liver resections per year), supported by the European-African Hepato-Pancreato-Biliary Association Education Committee (E-AHPBA), and the European Registry of Minimally Invasive Liver Surgery (E-MILS) aiming to support the step-up implementation and safety of advanced surgical expertise of robotic liver surgery (RLS) on a European basis. The LIVEROBOT training program aims to promote the safe implementation of RLS throughout Europe. The data from all patients operated on during a surgeons' participation in the training program will be prospectively gathered allowing for learning curve and outcome analyses.

NCT ID: NCT05495529 Completed - Neoplasm Metastasis Clinical Trials

Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors

Start date: January 1, 2013
Phase:
Study type: Observational

This study aims to analyse retrospectively the feasibility, the safety, and the efficiency, of biliary or digestive protection with room air interposition for thermal ablation of central liver tumors with high iatrogenic risk. Thermal ablation is a mini-invasive and curative treatement of liver tumors. However, it requires to be carefull about surrunding organs, such as digestive structures or central biliary tree, which can be injured if not insulated. The technique of gas interposition to protect adjacent gut is already known and validated with carbonic gas. Nevertheless, resorption of this gas is very fast, making its use tricky to keep a correct insulation during the whole thermal ablation process. Room air interposition is easy to use and can offer a slow resorption speed. Furthermore no datas are available concerning the use of room air whatever the organ protected, and the protection of central biliary tree whatever the gas used.

NCT ID: NCT05169177 Recruiting - Liver Neoplasm Clinical Trials

Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

ROCK-RT
Start date: October 17, 2022
Phase:
Study type: Observational

This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).

NCT ID: NCT04864054 Recruiting - Clinical trials for Hepatocellular Carcinoma

T-Cell Therapy (ECT204) in Adults With Advanced HCC

ARYA-3
Start date: March 11, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents. Phase I has concluded and a Recommended Phase II Dose (RP2D) has been determined. We are now conducting Phase II to further confirm the safety profile of ECT204 and evaluate its efficacy.

NCT ID: NCT04702230 Terminated - Liver Neoplasm Clinical Trials

Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization

Start date: September 11, 2017
Phase:
Study type: Observational

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and is commonly treated with transarterial locoregional therapies (transarterial chemoembolization (TACE) or transarterial radioembolization (TARE)). Early assessment of the effectiveness of transarterial locoregional therapies is critical for treatment planning and early identification of non-responders to allow a timely repeat treatment or conversion to a second-line local-regional or systemic treatment. Response of HCC to transarterial locoregional therapies is usually assessed by changes in tumor contrast material enhancement thought to reflect tumor viability. However, contrast material enhancement may not always accurately indicate tumor response as it may also reflect reactive changes rather than residual tumor tissue. A potential alternative for evaluation of the residual tumor is diffusion-weighted imaging (DWI), which can differentiate between tumor tissue with high cellularity and tumor necrosis. DWI has been shown useful in therapy response assessment of liver tumors. A further development of DWI is intravoxel incoherent motion imaging (IVIM), an MRI technique which also takes tumor perfusion and thus tumor viability into account. This makes IVIM a promising tool for early therapy response assessment in HCC patients. The primary objective is to proof that DWI and especially IVIM with its inherent perfusion information related to tumor neovascularization allows for reliable and quantitative monitoring of tumor response and separating responders from non-responders to either of the two locoregional treatments (TACE or TARE) The secondary objective is to identify whether DWI/IVIM acquired during early follow-up (1 month after treatment) leads to better response assessment than DWI/IVIM acquired during later follow-up (3 months after treatment). The primary outcome will be the DWI/IVIM values in patients responding to transarterial locoregional therapies of HCC compared to patients not responding to therapy according to mRECIST at 6 months The secondary outcome will be the number of patients correctly identified as responders at early follow-up (after 1 month) with DWI/IVIM compared to the number of patients correctly identified as resopnders at later follow-up (after 3 months).

NCT ID: NCT04502082 Terminated - Clinical trials for Hepatocellular Carcinoma

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Start date: April 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).

NCT ID: NCT04187937 Terminated - Liver Neoplasm Clinical Trials

Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections

Start date: June 17, 2020
Phase: N/A
Study type: Interventional

In a non-anatomical resection of a liver tumor, only the part of the liver with the tumor and a safety margin of 5 - 10 mm are resected. This is done to ensure a negative resection margin, which means that no tumor cells are at the boundary of the resection. These non-anatomical resections can be performed repeatedly in case of recurrence. However, compared to anatomical resections, it is more challenging to keep a negative resection margin as anatomical landmarks cannot be used for intra-operative guidance. In this study, the investigators aim to clinically evaluate a 3d navigation system, where navigated intra-operative ultrasound data is used to create a virtual model and a surgical plan.

NCT ID: NCT04010071 Recruiting - Clinical trials for Biliary Tract Neoplasms

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

The investigators design a phase II clinical study to explore the efficacy and safety of axitinib plus toripalimab as a second-line treatment in patients with hepatobiliary malignant tumors and to analyze potential biomarkers of therapeutic response.

NCT ID: NCT03998033 Terminated - Clinical trials for Hepatocellular Carcinoma

Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma

ET-109
Start date: May 30, 2019
Phase: Phase 1
Study type: Interventional

This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte Antigen (HLA) A-2 positive Hepatocellular Carcinoma (HCC).